MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 134 filers reported holding MERSANA THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $20,973,750 | -32.4% | 6,375,000 | -15.6% | 0.28% | -38.0% |
| Q1 2023 | $31,030,500 | -29.9% | 7,550,000 | 0.0% | 0.46% | -30.4% |
| Q4 2022 | $44,243,000 | -13.3% | 7,550,000 | 0.0% | 0.66% | -29.9% |
| Q3 2022 | $51,038,000 | +46.3% | 7,550,000 | 0.0% | 0.94% | +36.9% |
| Q2 2022 | $34,881,000 | +28.6% | 7,550,000 | +11.0% | 0.69% | +39.2% |
| Q1 2022 | $27,132,000 | -35.9% | 6,800,000 | 0.0% | 0.50% | -31.2% |
| Q4 2021 | $42,296,000 | -34.0% | 6,800,000 | 0.0% | 0.72% | -28.5% |
| Q3 2021 | $64,124,000 | -30.6% | 6,800,000 | 0.0% | 1.01% | -37.3% |
| Q2 2021 | $92,344,000 | -16.1% | 6,800,000 | 0.0% | 1.61% | -15.5% |
| Q1 2021 | $110,024,000 | -39.2% | 6,800,000 | 0.0% | 1.90% | -39.0% |
| Q4 2020 | $180,948,000 | +42.9% | 6,800,000 | 0.0% | 3.12% | +73.2% |
| Q3 2020 | $126,616,000 | -16.8% | 6,800,000 | +4.6% | 1.80% | -40.2% |
| Q2 2020 | $152,100,000 | – | 6,500,000 | – | 3.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 4,005,600 | $64,810,000 | 6.21% |
| Bain Capital Life Sciences Investors, LLC | 3,695,667 | $59,796,000 | 3.39% |
| COMMODORE CAPITAL LP | 429,228 | $6,945,000 | 2.77% |
| ACUTA CAPITAL PARTNERS, LLC | 357,689 | $5,787,000 | 2.09% |
| Avoro Capital Advisors LLC | 6,800,000 | $110,024,000 | 1.90% |
| Ghost Tree Capital, LLC | 450,000 | $7,281,000 | 1.71% |
| RHO CAPITAL PARTNERS INC | 796,458 | $12,887,000 | 1.24% |
| Rock Springs Capital Management LP | 2,775,127 | $44,902,000 | 0.98% |
| Sio Capital Management, LLC | 157,259 | $2,544,000 | 0.52% |
| Bellevue Group AG | 2,850,010 | $46,113,000 | 0.49% |